The Dutch Healthcare Authority recommends the adoption of new integrated funding for maternity care by 2028

30

Sep 2020

Almost every mother with her unborn child receives support from various professionals and organizations, the midwife, the gynecologist, the obstetric nurse, and the maternity nurse. The aim of integrated birth care is to increase the quality and safety of birth care and to reduce morbidity and mortality. Integrated maternity care focuses on the pregnant woman and her unborn child and stimulates collaboration between care professionals from different providers.

The policy rule for Integrated Birth Care was published by the Dutch National Authority for Health (NZa) on July 1, 2017. It contains nine services divided into three phases of birth care (prenatal, natal, postnatal), including:

  • Counseling ending before 16 weeks of pregnancy, including aftercare
  • Prenatal birth care
  • Complex prenatal birth care
  • Natal birth care
  • Natal birth care at the client's request
  • Complex natal birth care
  • Postnatal birth care
  • Complex postnatal birth care
  • Postnatal maternity care per hour

The aim of the policy rule is to lay down conditions under which it is possible to deviate from regular funding and to offer healthcare providers and healthcare insurers the option of agreeing on an experiment for the funding of integrated maternity care to promote cooperation in maternity care

After the adoption of the Policy Rule in 2017, the experiment on integral funding of maternity continues until January 1, 2022. On September 9, 2020, the NZa published advice on the timing of implementation of integrated funding for maternity care. The new funding model should be adopted by 2028 at the latest.

The full details in Dutch can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more